Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | SPHK1 | Q9NYA1 | 3/20 | 0.33 |
| ▸ | ALB | P02768 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | PAOX | Q6QHF9 | 2/20 | 0.32 |
| ▸ | TRPA1 | O75762 | 3/20 | 0.31 |
| ▸ | FNTA | P49354 | 1/20 | 0.31 |
| ▸ | FNTB | P49356 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13560704 | 0.98 | MEN1 (0.47) | MEN1CYP1A2KMT2ASMN1; SMN2ALOX15 | |
| SCHEMBL7058449 | 0.91 | — | — | |
| SCHEMBL10728146 | 0.83 | SMN1; SMN2 (0.53) | MEN1CYP1A2KMT2ASMN1; SMN2ALOX15 | |
| SCHEMBL7063396 | 0.82 | — | — | |
| SCHEMBL11882788 | 0.82 | SMN1; SMN2 (0.67) | MEN1CYP1A2KMT2ASMN1; SMN2ALOX15 | |
| SCHEMBL10728151 | 0.82 | SMN1; SMN2 (0.67) | MEN1CYP1A2KMT2ASMN1; SMN2ALOX15 | |
| SCHEMBL434733 | 0.82 | SMN1; SMN2 (0.67) | MEN1CYP1A2KMT2ASMN1; SMN2ALOX15 | |
| SCHEMBL3072659 | 0.82 | SMN1; SMN2 (0.67) | MEN1CYP1A2KMT2ASMN1; SMN2ALOX15 | |
| SCHEMBL1923256 | 0.82 | SMN1; SMN2 (0.67) | MEN1CYP1A2KMT2ASMN1; SMN2ALOX15 | |
| SCHEMBL3069140 | 0.82 | SMN1; SMN2 (0.67) | MEN1CYP1A2KMT2ASMN1; SMN2ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120277184-A1 | BLOCKERS OF PORE-FORMING VIRULENCE FACTORS AND THEIR USE AS ANTI-INFECTIVES | Innovative biologics, Inc (US) | 2012-11-01 | — | — | US | disclosed |
| US-20080234182-A1 | Compound having a symmetry and size capable of fitting to an opening of the pore of a pore-forming pathogen for binding such that upon binding, the pore or prepore is blocked, especially cyclodextrin derivatives; combatting biological warfare; drug screening; drug design | INNOVATIVE BIOLOGICS, INC. (US) | 2008-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234182-A1 | Compound having a symmetry and size capable of fitting to an opening of the pore of a pore-forming pathogen for binding such that upon binding, the pore or prepore is blocked, especially cyclodextrin derivatives; combatting biological warfare; drug screening; drug design | HAVCR2, GZMB, PRF1 | MEN1 1276/4885CYP1A2 4151/4885KMT2A 4815/4885 |
| US-20120277184-A1 | BLOCKERS OF PORE-FORMING VIRULENCE FACTORS AND THEIR USE AS ANTI-INFECTIVES | ANTXR2, LTA, GZMB | MEN1 4287/4885CYP1A2 3933/4885KMT2A 4224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.